Mineralys Therapeutics presented Phase 3 trial data showing lorundrostat significantly lowers systolic blood pressure in patients with and without chronic kidney disease (CKD). The drug also reduced albuminuria, a key marker of kidney damage, by over 50% in CKD patients, confirming earlier trial results. Lorundrostat demonstrated a good safety profile and is under FDA review with a decision expected by December 22, 2026. These results highlight lorundrostat's potential to treat hypertension and related kidney complications by targeting aldosterone production.
Mineralys Therapeutics' lorundrostat data presentation comes as 85 of 150 Health-sector US stocks tradable on Pluang rose today. For readers following this sector, here is Pluang's market snapshot as of Oct 23, 2026 05:32 WIB: SLS (SELLAS Life Sciences Group Inc.) fell 6.51% to USD 11.35 with a typical hold time of 4 days; CTXR (Citius Pharmaceuticals Inc.) dropped 6.42% to USD 0.37 but saw 100% buy order activity and a typical hold time of 18 days; INO (Inovio Pharmaceuticals Inc.) rose 5.76% to USD 0.84 with a typical hold time of 43 days and 73% sell order activity.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
